C-75 | Comparison of the Cost of Care of Eluvia versus Zilver PTX in Treating Femoropopliteal Artery Disease

Despite the use of endovascular femoropopliteal artery interventions (FPA), limited data exist regarding FPA intervention cost implications. This study quantified the cost of care during the index procedure and up to 2 years post-discharge for FPA patients treated with EluviaTM or Zilver® PTX®. A retrospective cohort study was conducted using the Premier PINC AITM Healthcare Database. All patients who underwent lower extremity FPA endovascular revascularization procedures with Eluvia (Boston Scientific, Marlborough, MA, USA) or Zilver PTX (Cook Incorporated, Bloomington, IN USA) between 3/1/2018 and 3/31/2022 were identified. Multivariable gamma log-link regression was used to compare the total cost of care from the healthcare perspective of Eluvia and Zilver PTX at index, 1 year, and 2 years, adjusting for patient and clinical characteristics. A total of 1,449 Eluvia and 3,068 Zilver PTX patients who underwent FPA revascularization were identified. The majority were male (59.0% vs. 59.9%), aged ≥65 (62.7% vs. 62.6%), and had higher prevalence of chronic limb-threatening ischemia (CLTI) (58.4% vs. 55.0%) in the Eluvia vs Zilver PTX cohort, respectively. At index, the mean adjusted cost of care among Eluvia patients was higher (difference: $1,178) but significantly lower at post-discharge (1-year, -$1,811; and 2-years, -$2,831). Among CLTI patients, the adjusted cost of care at index was higher for Eluvia than Zilver PTX (difference: $357). Post-discharge, Eluvia patients had significantly lower costs of care at 1 year (difference: -$4,419) and 2 years (difference: -$5,667) compared to the Zilver PTX. Similar patterns of variations in the adjusted cost of care were found by type of setting (inpatient and outpatient), with lower costs of care post-discharge among Eluvia than Zilver PTX patients. This study provides important insights into the potential long-term savings of FPA endovascular revascularization, with Eluvia demonstrating significantly lower costs than Zilver PTX at one and two years. Future research may explore the clinical and economic factors influencing these outcomes.